bioAffinity Technologies, Inc. (BIAF)
NASDAQ: BIAF · Real-Time Price · USD
0.3068
-0.0032 (-1.03%)
At close: Jul 11, 2025, 4:00 PM
0.3129
+0.0061 (1.99%)
After-hours: Jul 11, 2025, 6:39 PM EDT
bioAffinity Technologies Revenue
bioAffinity Technologies had revenue of $1.85M in the quarter ending March 31, 2025, a decrease of -22.97%. This brings the company's revenue in the last twelve months to $8.81M, up 78.40% year-over-year. In the year 2024, bioAffinity Technologies had annual revenue of $9.36M with 269.68% growth.
Revenue (ttm)
$8.81M
Revenue Growth
+78.40%
P/S Ratio
0.48
Revenue / Employee
$154,548
Employees
57
Market Cap
8.45M
Revenue Chart
Revenue History
Fiscal Year End | Revenue | Change | Growth |
---|---|---|---|
Dec 31, 2024 | 9.36M | 6.83M | 269.68% |
Dec 31, 2023 | 2.53M | 2.53M | 52,627.44% |
Dec 31, 2022 | 4.80K | - | - |
Dec 31, 2021 | - | - | - |
Dec 31, 2020 | - | - | - |
Sources: Historical revenue is based on company filings submitted to the U.S. Securities and Exchange Commission (SEC). The most recent revenue numbers may be taken from company press releases.
Revenue Definition
Revenue, also called sales, is the amount of money a company receives from its business activities, such as sales of products or services. Revenue does not take any expenses into account and is therefore different from profits.
Full DefinitionRelated Stocks
Company Name | Revenue |
---|---|
UnitedHealth Group | 410.06B |
Johnson & Johnson | 89.33B |
Merck & Co. | 63.92B |
AbbVie | 57.37B |
AstraZeneca | 54.98B |
Novartis AG | 53.22B |
Eli Lilly and Company | 49.00B |
Novo Nordisk | 43.92B |
BIAF News
- 16 days ago - bioAffinity Technologies Scientists Present Breakthrough Cancer Research at RNA Therapeutics Conference - Business Wire
- 18 days ago - bioAffinity Technologies Expands Patent Portfolio with China Grant for siRNA-Based Cancer Therapy - Business Wire
- 4 weeks ago - bioAffinity Technologies President and CEO Maria Zannes Appointed to American Lung Association in Texas' Leadership Board - Business Wire
- 6 weeks ago - bioAffinity Technologies Announces New U.S. Patent for Novel Broad Spectrum Cancer Therapeutics - Business Wire
- 7 weeks ago - bioAffinity Technologies Appoints Dr. Gordon Downie, MD, PhD, as Chief Medical Officer - Business Wire
- 2 months ago - bioAffinity Technologies Reports First Quarter 2025 Results - Business Wire
- 2 months ago - Independent White Paper Highlights Real-World Impact of bioAffinity Technologies' CyPath® Lung in Diagnosing Early-Stage Lung Cancer - Business Wire
- 2 months ago - WallachBeth Capital Announces Closing of bioAffinity Technologies $3.25m Offering - PRNewsWire